When Should Renal Replacement Therapy for Acute Kidney Injury Be Initiated and Discontinued?

R.T. Noel Gibney\textsuperscript{a, c} S.M. Bagshaw\textsuperscript{a, c} D.J. Kutsogiannis\textsuperscript{a, d} C. Johnston\textsuperscript{a, b, d}

\textsuperscript{a}Division of Critical Care Medicine, \textsuperscript{b}Division of Nephrology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, \textsuperscript{c}General Systems Intensive Care Unit, University of Alberta Hospital, and \textsuperscript{d}Intensive Care Unit, Royal Alexandra Hospital, Edmonton, Alta., Canada

**Conclusions:** Numerous studies consistently point toward a survival benefit to early initiation of RRT; however, there is a paucity of high-quality randomized trials. If early RRT is associated with clinical benefit, it remains uncertain whether this is attributable to more rapid metabolic/uremic control, management of fluid balance or a combination of clinical factors. In addition, timing of RRT initiation is likely context-specific and varies by clinical factors and/or etiology of AKI. There is also little data to accurately distinguish in advance between the injured kidney that will need extracorporeal renal support and one that retains capacity for early recovery. Fewer studies have evaluated the process of weaning of RRT or ideal methods to predict sufficient recovery to avoid re-initiation. Longer duration of RRT support, higher illness severity and lower urine output (independent of diuretic therapy) have all predicted need for re-initiation. Additional investigations on these issues are clearly warranted and urgently needed.

**Key Words**
Hemodialysis • Hemofiltration • Continuous renal replacement therapy • Acute renal failure • Acute kidney injury • Volume overload • Hyperkalemia

**Abstract**

**Background:** Critically ill patients with acute kidney injury (AKI) are at high risk for death and frequently require initiation of renal replacement therapy (RRT). There is wide variation in clinical practice on the indications for and timing of initiation and discontinuation of RRT. Numerous clinical and biochemical factors (i.e. uremic, metabolic, fluid balance) have been used; however, at present there is no consensus to guide clinicians on the most favorable time to initiate and/or discontinue RRT to optimize patient outcomes. **Methods:** In this review, we appraise the available clinical studies that have assessed timing of initiation and/or discontinuation of RRT for critically ill patients with AKI. ‘Timing’ of initiation has been variably defined including use of conventional biomarkers (i.e. serum urea and creatinine), urine output, fluid balance, and time relative to intensive care unit admission.
Introduction

Despite the longstanding and widespread use of renal replacement therapy (RRT) in acute kidney injury (AKI), there remains controversy about the optimal delivery of RRT, especially with respect to dose prescription and mode [1–16]. In practice, however, the provision of RRT in patients with AKI is extremely variable and based primarily on empiricism, local institutional practice and resources [17–22]. Evidence for the benefit of RRT in the acute setting is based largely on the known and highly lethal outcome of untreated AKI before the availability of extracorporeal dialysis, on early case series, and on extrapolation of the experience in chronic kidney disease (CKD) [23–25]. However, evidence on long-term follow-up of patients with AKI is limited. While the application of RRT improves short-term survival in patients with severe AKI, emerging data also suggests the long-term prognosis may be modified by AKI and characterized by impartial or non-recovery of kidney function, progression to CKD and greater long-term risk of death in survivors [26–28].

The use of newer classification systems, such as the RIFLE criteria, which have now been extensively validated, will greatly help to provide a more consistent approach to the comparative evaluation and research investigation for critically ill patients with AKI [29–40]. There is also strong evidence not only that the development of AKI is an independent factor for mortality in critically ill patients, but also that increasing severity of AKI, as measured by RIFLE classification, is directly associated with higher mortality [32–34, 40–42].

Despite this emerging agreement on the definition and impact of AKI, there remains no consensus on the optimal time to initiate or discontinue RRT in terms of serum biomarkers (i.e. creatinine, urea), fluid volume status or RIFLE staging. Since the natural history of AKI also varies by the cause, the effect of early initiation of RRT may also be influenced by the etiology of the AKI [43]. In general, there is agreement that RRT should be initiated as ‘rescue therapy’ when patients develop life-threatening complications associated with acute renal failure (i.e. hyperkalemia, pulmonary edema, uremic complications). However, outside of these indications, there is little consensus to guide clinicians on the appropriate time for initiation and discontinuation of RRT [32, 33, 44–51]. In reality, local resources including staffing, machine availability, and budget have a major influence on RRT resources such as timing of initiation, dose and frequency of RRT. In this review, we discuss the available data on the optimal time for the initiation and discontinuation of RRT in critically ill patients with AKI.

When Should Acute Extracorporeal Renal Support Be Initiated?

While there is general agreement on the value of RRT in established AKI, in particular when associated with oligoanuria, there is little agreement with regard to the optimal time of initiation and there is no accepted definition of what ‘timing of initiation’ represents. Currently, the term ‘timing’ for RRT may be variably interpreted as the timing from hospital admission, timing from ICU admission or timing from acute insult or, more commonly, as a proxy for timing when using arbitrary biochemical thresholds for serum urea and/or creatinine or measures of fluid balance [48, 52–63]. Consequently, there is wide variation in clinical practice [17–22].

‘Timing’ of RRT Initiation Defined by Surrogate Biochemical Markers

The majority of the literature on timing of RRT initiation uses threshold serum levels of urea or creatinine [64]. The assumption is that uremic illness is due to the accumulation of organic waste factors, not all understood, that are normally cleared by the kidney but are toxic to the patient [65]. With a paucity of clinical trials to guide timing of initiation of RRT, clinicians are left to make inferences based on retrospective studies with historical controls and cohort studies of variable quality. In a seminal study comparing randomized controlled trials with studies using historical controls across six therapeutic topics, Sacks et al. [66] showed that studies incorporating historical controls were more likely than randomized trials to find a therapeutic difference despite similar outcomes in the treatment group. Since many of the older studies on the timing of RRT incorporate historical controls, it is important to view the results in the context of this potential bias.

Teschan et al. [24] introduced the idea of ‘prophylactic dialysis’ in soldiers injured during the Korean War. In 15 patients with acute oliguric renal failure, hemodialysis was ‘prophylactically’ initiated at blood urea nitrogen (BUN) values ≤100 mg/dl (serum urea 35.7 mmol/l). Overall mortality in this series was only 33%.
While not a randomized trial, the authors concluded that the mortality in these patients was significantly lower than their previous historical experience where hemodialysis was typically initiated for more traditional ‘rescue therapy’ indications such as the development of uremic complications, hyperkalemia and/or pulmonary edema.

In the 1960s and 1970s, similar improvements in clinical outcome with early and/or more intensive hemodialysis were described [67–70] (table 1). In a small non-randomized study enrolling 33 patients with postoperative AKI, Parsons et al. [70] showed earlier (BUN ≤120–152 mg/dl [urea 43–54 mmol/l]) as compared with later (BUN ≥200 mg/dl [urea 71 mmol/l]) initiation of hemodialysis was associated with a significant reduction in the risk of death (25% for early vs. 88% for late, risk ratio [RR] 0.16, 95% CI 0.04–0.60, p < 0.001). Several additional small studies found comparable benefit with earlier initiation of intermittent hemodialysis (IHD), defined by lower BUN levels, in patients with AKI. Fischer et al. [67] retrospectively analyzed data from 162 patients with AKI requiring IHD and classified those started on RRT with a BUN >150 mg/dl (urea 54 mmol/l) as early and those with a BUN <150 mg/dl (urea 54 mmol/l) as delayed. Survival in the early RRT group was 46% compared with only 26% in the delayed RRT group. During the Vietnam War, Conger [71] studied 18 soldiers with posttraumatic AKI. Patients were assigned alternately to intensive IHD to maintain a predialysis BUN <70 mg/dl (urea 25 mmol/l) and serum creatinine <5 mg/dl (442 μmol/l), or to a non-intensive IHD regimen aimed to maintain a BUN <150 mg/dl (urea 54 mmol/l), a serum creatinine <10 mg/dl (884 μmol/l) and for treatment of any life-threatening clinical indications for dialysis. Five of 8 patients (64%) survived in the intensive IHD group compared to 2 of 10 (20%) in the non-intensive IHD group (p < 0.14). In addition to the apparent survival benefit, major complications, including gastrointestinal bleeding and sepsis, were less frequent in the intensive IHD group [71]. Kleinknecht et al. [69] reported a large cohort of 500 patients with AKI treated between 1966 and 1970. ‘Prophylactic’ hemodialysis to maintain a serum BUN <92 mg/dl (urea 33 mmol/l) was provided to 221 patients and compared with 279 historical controls who received usual care in which hemodialysis was initiated if the BUN was >165 mg/dl (urea 59 mmol/l) or in the presence of other acute indications (i.e. severe electrolyte disturbance). Those treated with earlier ‘prophylactic’ hemodi-

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Number</th>
<th>Study design</th>
<th>BUN, mg/dl early</th>
<th>BUN, mg/dl delayed</th>
<th>Mortality, % early</th>
<th>Mortality, % delayed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parsons [70]</td>
<td>1961</td>
<td>33</td>
<td>R</td>
<td>43–54</td>
<td>&gt;72</td>
<td>25</td>
<td>88</td>
</tr>
<tr>
<td>Fischer [67]</td>
<td>1966</td>
<td>162</td>
<td>R</td>
<td>54</td>
<td>&gt;72</td>
<td>57</td>
<td>74</td>
</tr>
<tr>
<td>Kleinknecht [69]</td>
<td>1972</td>
<td>500</td>
<td>R</td>
<td>33</td>
<td>59</td>
<td>29</td>
<td>42</td>
</tr>
<tr>
<td>Conger [71]</td>
<td>1975</td>
<td>18</td>
<td>P, C</td>
<td>18</td>
<td>43</td>
<td>20</td>
<td>64</td>
</tr>
<tr>
<td>Gillum [68]</td>
<td>1986</td>
<td>34</td>
<td>P, C</td>
<td>22</td>
<td>36</td>
<td>59</td>
<td>47</td>
</tr>
<tr>
<td>Lange [102]</td>
<td>1987</td>
<td>36</td>
<td>R</td>
<td>&lt;80</td>
<td>&gt;80</td>
<td>43</td>
<td>67</td>
</tr>
<tr>
<td>Gettings [57]</td>
<td>1999</td>
<td>100</td>
<td>R</td>
<td>43</td>
<td>95</td>
<td>61</td>
<td>80</td>
</tr>
<tr>
<td>Bouman [46]</td>
<td>2002</td>
<td>106</td>
<td>RCT</td>
<td>45</td>
<td>105</td>
<td>29</td>
<td>25</td>
</tr>
<tr>
<td>Tsai [103]</td>
<td>2005</td>
<td>98</td>
<td>R</td>
<td>&lt;80</td>
<td>&gt;80</td>
<td>63</td>
<td>97</td>
</tr>
<tr>
<td>Liu [59]</td>
<td>2006</td>
<td>243</td>
<td>P, C</td>
<td>&lt;76</td>
<td>&gt;76</td>
<td>35</td>
<td>41</td>
</tr>
<tr>
<td>Bagshaw [45]</td>
<td>2008</td>
<td>1,238</td>
<td>P, C</td>
<td>&lt;68</td>
<td>&gt;68</td>
<td>63</td>
<td>61</td>
</tr>
</tbody>
</table>

P = Prospective, R = retrospective; C = cohort; RCT = randomized clinical trial.
To convert BUN (mg/dl) to urea (mmol/l) multiply by 0.357.
alysis experienced fewer uremic complications and had a 30% lower risk of death (RR 0.70, 95% CI 0.54–0.89, p < 0.01).

However, the study by Gillum et al. [68] showed no benefit with early RRT. In this small randomized trial of 34 patients with AKI, patients were allocated to receive either ‘intensive’ hemodialysis to maintain BUN <60 mg/dl (<21 mmol/l) and serum creatinine <5 mg/dl (<442 μmol/l) or to a ‘less intensive’ regimen to maintain BUN <100 mg/dl (<36 mmol/l) and serum creatinine <9 mg/dl (<326 μmol/l). There were no significant differences in survival between the intensive and less intensive groups; however, this trial was not really designed to evaluate the timing of initiation of RRT. Notably, all patients had serum creatinine values ≥8 mg/dl (≥707 μmol/l) at the time RRT was initiated. In addition, there were marked differences in illness severity between the groups, making inferences about timing difficult.

Within the last decade, two retrospective observational studies have shown improved survival when RRT was initiated early when defined arbitrarily by lower serum urea levels [57, 59]. In a small cohort of critically ill patients with posttraumatic AKI receiving continuous RRT, Gettings et al. [57] used a cut-off of a BUN ≥60 mg/dl (≥21.4 mmol/l) to evaluate the impact of early vs. delayed ‘timing’ of intervention on survival. The ‘early’ group had a mean BUN 42.6 mg/dl (15.2 mmol/l) compared with the ‘delayed’ group having a mean BUN 94.5 mg/dl (33.7 mmol/l) (p < 0.0001). Both the early and delayed groups, however, likely had relatively late RRT initiation. The ‘early’ group had CRRT (continuous RRT) initiated 10 days after hospital admission whereas the ‘delayed’ had RRT started 19.4 days after presentation. The overall mortality for the entire cohort was high; however, the mortality for early compared with delayed RRT was significantly lower (61% for early vs. 80% for delayed; RR 0.77, 95% CI 0.58–1.0, p = 0.04).

In a more recent secondary analysis of a prospectively collected AKI database, Liu et al. [59] found a significant higher risk of death at 60 days when initiation of RRT was delayed, defined by a serum urea level ≥76 mg/dl (≥27.1 mmol/l), compared with earlier commencement. After covariate adjustment in multivariable analysis, including for age, hepatic failure, sepsis, thrombocytopenia, serum creatinine, study site and initial dialysis modality, the RR for death associated with delayed initiation of RRT was 1.85 (95% CI 1.16–2.96) [59].

In the classic CVVH (continuous veno-venous hemofiltration) dose trial by Ronco et al. [10], where survival was significantly improved in those patients treated with 35 ml/kg/h when compared with 20 ml/kg/h, a higher BUN at the time of initiation of CVVH was independently associated with lower survival (adjusted hazards ratio [HR] 1.05, 95% CI 1.04–1.07). Similarly, in the dose trial by Saudan et al. [11], comparing CVVH with CVVHDF (CVV hemodiafiltration), baseline BUN was found to be independently associated with 28-day and 90-day mortality (p = 0.008).

These data would indicate that earlier initiation of RRT, prior to significant retention of uremic solutes, potentially exerts an important influence on survival that is also independent of therapeutic RRT dose prescribed. However, only one small and underpowered randomized trial has evaluated the impact of both timing and dose on clinical outcome [46]. Bouman et al. [46] examined the effect of timing of CVVH on outcome in 106 critically ill ventilated patients with oliguric AKI, and found no significant benefit to early or high-intensity CVVH whether timing was defined by either time from development of oliguria or by BUN threshold. However, inferences from this study are limited due to the small sample size, the predominantly cardiac surgical population and the surprisingly high survival rate (i.e. low mortality event rate).

‘Timing’ of RRT Initiation Defined by Time of Onset of Oliguria

Sugahara et al. [63] employed urine output as a criterion for initiation of CRRT in a small randomized trial of 28 critically ill patients following cardiac surgery. Patients were enrolled when urine output fell below 30 ml/h and the serum creatinine increased ≥0.5 mg/dl (≥44.2 μmol/l) within 24 h. The early initiation group (n = 14) had RRT started when urine output was <30 ml/h for three consecutive hours (daily urine output <750 ml). The delayed group (n = 14) had CRRT started when urine output reached <20 ml/h for two consecutive hours (daily urine output <500 ml). At baseline, the early and delayed groups were well matched, including for serum creatinine and illness severity. Mean urine output was preserved for the first several days in the early start group and began to increase on day 6 of CVVHDF (CVV hemodialysis), with a difference from baseline becoming significant by day 8. In the delayed start group, the mean urine output decreased during the first 3 days of CVVHDF and, although it increased subsequently, the change from baseline was never significant over the 14-day period of...
evaluation. Moreover, survival at 14 days was significantly higher in the early group vs. the delayed group (86 vs. 14%, p < 0.01).

'Timing' of RRT Initiation Defined by Duration from ICU Admission

While the majority of studies have generally used a metabolic/solute threshold such as serum urea as a proxy for timing of initiation of RRT, there is some evidence that timing of RRT in critically ill patients with AKI relative to admission to ICU may have prognostic importance. Cosentino et al. [54] found, in a cohort of 363 critically ill patients with AKI, that temporal delay from ICU admission to start of RRT (i.e. increase in the number of days) was independently associated with mortality.

Three retrospective single-center studies of critically ill patients with AKI following cardiac surgery have shown improved survival with earlier initiation of CRRT, defined temporally as the number of hours/days after surgery [55, 56, 72]. Bent et al. [72] compared 65 consecutive patients who developed AKI following cardiac surgery treated with early intensive CVVH to historical controls. The average time between surgery and the start of CVVH was 2.4 days. The predicted mortality in this population was 66%, based on the Liano prediction model, while the observed mortality was only 40% (p = 0.003), suggesting early intensive RRT for AKI complicating cardiac surgery can improve survival [73]. Elahi et al. [56] evaluated the impact of initiation of RRT early in the postoperative period for critically ill cardiac surgery patients with AKI. Of the 1,264 patients who had cardiac surgery over a 1-year period, 64 (5%) required RRT for AKI. Patients were divided into two categories: 'early CRRT' defined by initiation of CRRT when the urine output reached ≤100 ml during a consecutive 8-hour period, regardless of the biochemical parameters, and 'delayed CRRT' defined by initiation of CRRT upon fulfilling any of the following criteria: BUN ≥84 mg/dl (≥30 mmol/l), creatinine ≥2.8 mg/dl (≥248 μmol/l), or potassium ≥6.0 mmol/l, regardless of urine output. Overall, this cohort was characterized by relatively advanced age (mean 70 years), and a high prevalence of both congestive heart failure (56% NYHA class 3 or 4) and CKD (baseline creatinine 1.8 mg/dl [159 μmol/l]). The average time to CRRT initiation after surgery was 18 h in the early CRRT group compared with 61.2 h in the delayed CRRT group (p < 0.001). This difference in 'timing' was associated with a significantly lower BUN in the early vs. delayed group (67 mg/dl [23.9 mmol/l] vs. 75 mg/dl [26.8 mmol/l], p < 0.05), respectively. While the median duration of CRRT was similar between the two groups, the early CRRT group had a significantly lower hospital mortality compared with those receiving delayed CRRT (22% for early vs. 43% for late, p < 0.05). This may, in part, be attributable to a lower rate of multiorgan failure developing in the early CRRT group compared with those that were delayed CRRT (19% for early vs. 29% for late, p = 0.01). Furthermore, the average duration of ICU and hospital stay were both significantly reduced in those receiving early CRRT (8.5 days in ICU for early vs. 12.5 days for delayed, p < 0.05; 15.4 days in hospital for early vs. 20.9 days for delayed, p < 0.05). In a nearly identical clinical study, Demirkilic et al. [55] evaluated early intensive CVVHDF compared with conservative usage of CVVHD in 61 critically ill patients with AKI after cardiac surgery and found similar results. The average time between surgery and initiation of CVVHDF was 61 h in the delayed group compared with 19.2 h in the early group (p = 0.0001). Likewise, the average length of stay in ICU was considerably shorter for early CRRT compared with delayed (7.9 days for early vs. 12 days for delayed, p = 0.0001). Finally, both ICU and hospital mortality were higher for delayed CRRT when compared with early CRRT (ICU: 48.1% for delayed vs. 17.6% for early, p = 0.014; hospital: 55.5% for delayed vs. 23.5% for early, p = 0.016). As with the study of Bent et al. [72], the delayed group in this study were historical controls, which limits inferences.

More recently, in a small observational study with historical controls, Andrade et al. [52] compared outcomes based on the 'door-to-dialysis' time and frequency of IHD in critically ill patients with leptospirosis-induced AKI, septic shock and multiorgan dysfunction. Patients were compared by treatment strategies of either alternate day IHD and daily IHD. While there was no difference between the groups in BUN levels at the time of RRT initiation, a shorter measured 'door-to-dialysis' time and daily IHD was associated with significantly higher survival compared with delayed and alternate day IHD (83.3% for early and daily vs. 33.3% for delayed and alternate day). However, inferences are limited due to issues of study design and confounding.

Recently, the Beginning and Ending Supportive Therapy for the Kidney (BEST) investigators reported findings from a secondary analysis of their database on the timing of RRT and clinical outcomes in 1,238 critically ill...
patients [45]. The BEST Kidney Study was a prospective, multinational, multicenter observational cohort study of critically ill patients with severe AKI performed at 54 centers across 23 countries [51]. This analysis found important differences in clinical outcomes when ‘timing’ of initiation of RRT was defined by median values of serum urea, serum creatinine or temporally from the date of ICU admission. Timing of RRT was stratified into ‘early’ and ‘late’ by median serum urea and creatinine levels at the time RRT was started. Timing was also categorized temporally from ICU admission into early (<2 days), delayed (2–5 days), and late (>5 days). Timing of RRT by serum urea at RRT initiation showed no significant difference in crude or covariate-adjusted mortality. When stratified by serum creatinine, late RRT was associated with lower crude mortality (53.4% for creatinine >3.5 mg/dl [309 μmol/l] vs. 71.4% for creatinine ≤3.5 mg/dl [309 μmol/l]; OR 0.46; 95% CI 0.36–0.58, p < 0.001) and covariate-adjusted mortality (OR 0.51, 95% CI 0.37–0.69, p < 0.001). However, for ‘timing’ relative to ICU admission, late RRT was associated with greater crude mortality (72.8% for late vs. 62.3% for delayed vs. 59% for early, p < 0.001) and covariate-adjusted mortality (OR 1.95, 95% CI 1.30–2.92, p < 0.001). Overall, late RRT, however defined, was also associated with a longer duration of RRT, longer stay in hospital and a lower rate of renal recovery to dialysis independence at hospital discharge [45].

The recently reported ATN study, a large multicenter randomized trial of 1,124 critically ill patients with AKI, showed no meaningful difference in 60-day mortality between intensive and less intensive RRT (53.6% for intensive vs. 51.5% for less intensive, p = 0.47). However, while the average BUN values were nearly identical at RRT initiation (65.9 mg/dl [23.5 mmol/l] vs. 66.7 mg/dl [23.8 mmol/l]), regardless of modality, it is noteworthy that the average time from ICU admission to RRT initiation was ≥6 days in both groups [13]. Similarly, in the randomized trial by Tolwani et al. [109] comparing high-dose to standard-dose CVVHDF in 200 critically ill patients with AKI, the average time from ICU admission to RRT initiation was 8 days. These data are in contrast with the BEST Kidney Study and the trial by Ronco et al. where the average time from ICU admission to RRT initiation was 1–1.6 days, respectively [10, 45].

‘Timing’ of RRT Based on Fluid Volume Status

There is clear consensus on the importance of fluid therapy in the acute resuscitation of critically ill patients [74]. Moreover, the administration of fluid therapy is common and it is likely that all patients receive variable amounts of intravenous fluid therapy during an episode of critical illness. Fluid therapy also represents a central cornerstone for the prevention and/or the management of AKI in critical illness [75, 76]. Of the numerous strategies evaluated to date for the prevention of AKI, only fluid therapy has been found consistently effective [75]. However, there is no evidence fluid therapy will reverse AKI once established. In fact, evidence has accrued to indicate that the unnecessary accumulation of fluid (i.e. fluid overload) can negatively impact clinical outcomes in critically ill patients [77–79]. This may be particularly evident for fluid overloaded oliguric patients with AKI who fail to adequately respond to a diuretic challenge.

In addition, the avoidance of volume overload represents a huge clinical challenge in the critically ill, in particular for those with AKI, and represents a common indication for RRT [80–85]. Similarly, oliguria in AKI, in the absence of clear hypovolemia, is not necessarily an indication for a fluid challenge. The distinction is important. In the context of hypovolemia and/or reduced effective circulating volume, fluid therapy is clearly indicated. However, there is no evidence to support a fluid challenge in the resuscitated critically ill patient with oliguric AKI. While such a fluid challenge may indeed temporarily increase urine flow, there is no data to indicate that such a fluid challenge attenuates the severity of AKI or improves clinical outcome. Instead, the liberal use of fluid therapy in these circumstances may contribute to or exacerbate volume overload and lead to harm (table 2). For example, in a small cohort of critically ill patients with sepsis-induced AKI, Van Biesen et al. [77] found that, despite resuscitation characterized by optimal hemodynamics and restored intravascular volume and despite an already high use of diuretic therapy, additional fluid therapy not only failed to improve kidney function but led to unnecessary volume overload, impaired gas exchange and pulmonary edema.

Recently, Upadya et al. [86] found that maintenance of a negative fluid balance independently predicted weaning success in critically ill mechanically ventilated patients. Likewise, several studies have now shown improved survival, fewer ventilator-days and/or reduced duration of ICU stay in patients with ARDS/ALI by
adoption of a conservative fluid management strategy essentially aimed at maintaining a neutral fluid balance [78, 79]. In a small retrospective study, Alsous et al. [87] found an increased risk of death for critically ill patients with septic shock failing to achieve a negative fluid balance within the first 3 days of treatment (RR 5.0, 95% CI 2.3–10.9, p < 0.0001).

Moreover, emerging data would suggest that avoidance of fluid overload with CRRT can improve clinical outcomes, especially in critically ill children with AKI

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Patients</th>
<th>Design</th>
<th>Population</th>
<th>Intervention</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simmons [104]</td>
<td>1987</td>
<td>113</td>
<td>P, C</td>
<td>ARDS</td>
<td>N/A</td>
<td>Mortality associated with positive daily/ cumulative fluid balance and weight gain</td>
</tr>
<tr>
<td>Schuller [105]</td>
<td>1991</td>
<td>89</td>
<td>R, C</td>
<td>ALI/ARDS</td>
<td>N/A</td>
<td>Mortality associated with higher positive fluid balance &gt;1 liter over 36 h (50 vs. 26%, p &lt; 0.05) along with longer duration of MV and ICU/hospital stay</td>
</tr>
<tr>
<td>Goldstein [88]</td>
<td>2001</td>
<td>21</td>
<td>R, C</td>
<td>Pediatric AKI</td>
<td>N/A</td>
<td>Mortality associated with higher %FO at RRT initiation (34 vs. 16.4%, p = 0.03)</td>
</tr>
<tr>
<td>Brandstrup [106]</td>
<td>2003</td>
<td>172</td>
<td>RCT</td>
<td>Elective colorectal surgery</td>
<td>Restrictive vs. standard perioperative fluid strategy</td>
<td>Restrictive strategy reduced postoperative weight gain and complications (33 vs. 51%, p = 0.003)</td>
</tr>
<tr>
<td>Goldstein [88]</td>
<td>2004</td>
<td>113</td>
<td>R, C</td>
<td>Pediatric AKI</td>
<td>N/A</td>
<td>Mortality associated with higher %FO at RRT initiation (15.5% vs. 9.2%, p = 0.01)</td>
</tr>
<tr>
<td>Gillespie [90]</td>
<td>2004</td>
<td>77</td>
<td>R, C</td>
<td>Pediatric AKI</td>
<td>N/A</td>
<td>Mortality associated with higher %FO at RRT initiation (&gt;10%, RR 3.02, p = 0.002)</td>
</tr>
<tr>
<td>Goldstein [107]</td>
<td>2005</td>
<td>116</td>
<td>R, C</td>
<td>Pediatric AKI</td>
<td>N/A</td>
<td>Mortality associated with higher %FO at RRT initiation (25.4% vs. 14.2%, p = 0.03)</td>
</tr>
<tr>
<td>Sakr [78]</td>
<td>2005</td>
<td>393</td>
<td>P, C</td>
<td>ALI/ARDS</td>
<td>N/A</td>
<td>Mortality associated with positive cumulative fluid balance (+4.4 vs. -3.0 l, OR 1.5, p = 0.003)</td>
</tr>
<tr>
<td>Uchino [108]</td>
<td>2006</td>
<td>331</td>
<td>P, NR</td>
<td>Critically ill</td>
<td>N/A</td>
<td>Mortality associated with positive fluid balance (OR 1.0002 per each ml/day, p &lt; 0.01)</td>
</tr>
<tr>
<td>Wiedemann [79]</td>
<td>2006</td>
<td>1,000</td>
<td>RCT</td>
<td>ALI/ARDS</td>
<td>Conservative vs. liberal fluid strategy</td>
<td>Conservative strategy had lower cumulative 7-day fluid balance (~0.13 vs. 6.9 l, &lt;0.001), improved gas exchange, shorter time on ventilator and ICU stay, no difference in rate of RRT or mortality</td>
</tr>
<tr>
<td>Payen [91]</td>
<td>2008</td>
<td>1,120</td>
<td>P, NR</td>
<td>Critically ill</td>
<td>N/A</td>
<td>Positive average fluid balance (per 1 liter/24 h) independently associated with 60-mortality (HR 1.21, p &lt; 0.001)</td>
</tr>
</tbody>
</table>

P = Prospective, R = retrospective; C = cohort; RCT = randomized clinical trial; NR = non-randomized; HR = hazard ratio; ALI = acute lung injury; ARDS = acute respiratory distress syndrome; N/A = not applicable; %FO = percentage fluid overload; RR = risk ratio; MV = mechanical ventilation.
and following cardiac surgery. Goldstein et al. [88] retrospectively evaluated 21 critically ill children with AKI requiring CRRT and found that non-survivors had a higher percentage of fluid overload at the time CRRT was initiated (34% for non-survivors vs. 16.4% for survivors, \( p = 0.03 \)). These findings were subsequently confirmed in two additional studies of critically ill children with AKI where risk of death was significantly increased in those with a greater positive fluid overload at the time CRRT was started [89, 90]. Gillespie et al. [90] conducted a retrospective review of 77 critically ill children who were treated with CVVH. Those with high fluid overload (>10%) at CVVH initiation had a >3-fold risk of death compared to those with little or no fluid overload (HR 3.0, 95% CI 1.5–6.1, \( p = 0.002 \)). Foland et al. [89] retrospectively studied 113 critically ill children requiring CVVH. Median percentage fluid overload at the time CRRT was initiated was significantly lower in survivors vs. non-survivors (7.8 vs. 15.1%, \( p = 0.02 \)).

Recently, Payen et al. [91] performed a secondary analysis of the Sepsis Occurrence in Acutely Ill Patients (SOAP) study, a large multicenter European observational cohort study, to evaluate the outcomes associated with AKI. Patients were compared by whether they developed AKI, defined according to the renal SOFA score as a creatinine >3.5 mg/dl (309 \( \mu \)mol/l) or a urine output <500 ml/day, or not. In addition, the study evaluated the timing of initiation of RRT and outcomes, where ‘early’ RRT was defined as commencing <2 days and ‘delayed’ if started ≥2 days after ICU admission. Of the 3,147 patients included in the study, 1,120 (36%) developed AKI at some point during their ICU stay. Mortality at 60 days was 36% for those with AKI and only 16% for those with no AKI (\( p < 0.01 \)). In patients with AKI, the average daily fluid balance was significantly more positive among non-survivors compared with survivors (1,000 vs. 150 ml, \( p < 0.001 \)). Those with oliguria and those treated with RRT had higher 60-day mortality compared to those without oliguria or having received RRT (oliguria: 41% for non-survivors vs. 33% for survivors, \( p < 0.01 \); RRT: 52% for non-survivors vs. 32% for survivors, \( p < 0.01 \)). Furthermore, for patients in whom treatment with RRT was started ‘early’ after admission to ICU, the median length of ICU stay was significantly shorter (6.1 days for early vs. 12.2 days for delayed, \( p < 0.001 \)) and 60-day mortality rate was significantly lower (44.8% for early vs. 64.6% for delayed, \( p < 0.01 \)). Attention to fluid balance and prevention of volume overload in critically ill patients with AKI may be an important determinant of outcome. Moreover, the prevention and/or management of volume overload may evolve as a key early trigger for extracorporeal fluid removal independent of solute clearance. This was evident in the recently reported ATN trial, where those allocated to alternate-day less intensive hemodialysis not uncommonly had inadequate control of fluid volume that mandated additional ‘off-protocol’ ultrafiltration sessions [13].

‘Timing’ of Discontinuation of RRT

There is a relative paucity of data about the process of discontinuation of RRT in critically ill patients with AKI. This lack of evidence contrasts with the field of mechanical ventilation, where many studies dealing with the process of ‘weaning’ from mechanical ventilation have been conducted [92–94].

In the trial by Bouman et al. [46], CRRT was discontinued when the urine output returned to and was stable at >60 ml/h. However, there was no data on whether discontinuation at different rates of urine output was more or less successful and whether failure to successfully wean from RRT led to variation in survival, renal recovery, re-initiation of RRT or other outcomes. Recently, Wu et al. [95] performed a retrospective case-control study to evaluate the timing of RRT discontinuation in 304 patients treated with IHD. 94 patients (30.9%) were weaned from RRT for 5 or more days, of which 64 (21.1%) were free from RRT for ≥30 days. Factors independently associated with re-initiation of RRT within 30 days included: longer duration of RRT, higher SOFA score, oliguria (≤100 ml in 8 h) and age ≥65 years.

Recently, the BEST Kidney investigators also evaluated the current practice of CRRT discontinuation to identify which factors present at the time of discontinuation may assist clinicians in predicting successful cessation of CRRT [96]. Approximately 50% of critically ill patients receiving CRRT had it discontinued while still otherwise undergoing full life-sustaining therapy. Urine output at cessation of CRRT was found to be the most important predictor of successful discontinuation of CRRT. A urine output of >400 ml/day without concomitant diuretic therapy had the best operative characteristics with a sensitivity, specificity, positive predictive value and negative predictive value of 0.47, 0.81, 0.81, and 0.77, respectively. At this cut-off, 78.6% were correctly classified. Patients whose CRRT was successfully discontinued without requirement for re-institution of RRT...
Conclusions

Despite many studies suggesting that early RRT is associated with improved clinical outcomes in patients with AKI, there are at present no suitably-powered randomized clinical trials to guide clinicians on what defines ‘early’ and what clinical factors or thresholds are ideal for the decision to initiate RRT ‘early’ [97]. There is virtually no data to accurately distinguish in advance the injured kidney that will need extracorporeal organ support from the injured kidney that retains capacity for early recovery. Moreover, if there is clinical benefit to early initiation of RRT, it remains unclear whether this benefit may be attributable to earlier clearance and control of uremic toxins and solutes, prevention and management of volume overload, or a combination of both or to additional factors not yet elucidated. Clearly, further studies in this area are needed [97]. These will be challenging to perform and will require a large enough number of subjects to detect clinically relevant differences in key outcomes such as survival and recovery of kidney function. Such a trial should strive to discriminate potential differences in clinical outcome attributable to achieving metabolic control versus fluid balance control. One of the most difficult issues in AKI is determining the exact time of onset and magnitude and/or severity of injury to the kidney. Regrettably, conventional biomarkers such as serum urea and creatinine perform poorly and are commonly inconsistent [98]. Consequently, new studies evaluating the timing of RRT in AKI should also incorporate newer biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18) and/or cystatin C in order to better determine the onset, severity, persistence and response to intervention for patients with AKI accurately [99–101].

References

29 Abosaif NY, Tolba YA, Heap M, Russell J, El McCarthy JT: Prognosis of patients with
23 Bell M, Liljestam E, Granath F, Fryckstedt J,
27 Bagshaw SM, George C, Bellomo R: Changes
25 Woodrow G, Turney JH: Cause of death in
22 Ricci Z, Ronco C, D'Amico G, De Felice R,
20 Mendelssohn DC, Mullaney SR, Jung B,
23 McCarthy JT: Prognosis of patients with
30 Bellomo R, Kellum JA, Ronco C: Defining
RIFLE: model application, sensitivity, and
ure in the intensive care unit according to
Nahas AM: The outcome of acute renal fail-
R700–R709.

31 Bellomo R, Ronco C, Kellum JA, Mehta RL,
38 Uchino S, Bellomo R, Goldsmith D, Bates S,
34 Hoste EA, Kellum JA: Incidence, classifica-
156, pp 32–38.

32 Bellomo R, Ronco C, Kellum JA, Mehta RL,
Paleyves P: Acute renal failure – definition,
outcome measures, animal models, fluid
therapy and information technology needs:
the Second International Consensus Confer-
ence of the Acute Dialysis Quality Initiative
(ADQI) Group. Crit Care 2004;8:R204–
R212.

33 Hoste EA, Clermont G, Kersten A, Venkatar-
raman R, Angus DC, De Bacquier D, Kellum
JA: RIFLE criteria for acute kidney injury are
associated with hospital mortality in criti-

34 Hoste EA, Kellum JA: Incidence, classifica-
tion, and outcomes of acute kidney injury.

35 Kuitunen A, Vento A, Suojaranta-Ylen R,
Pettila V: Acute renal failure after cardiac
surgery: evaluation of the RIFLE classifica-

36 Lopes JA, Jorge S, Neves FC, Caneira M, da
Costa AG, Ferreira AC, Prata MM: An as-
essment of the rifle criteria for acute renal

37 Lopes JA, Jorge S, Silva S, de Almeida E,
Abreu F, Martins C, do Carmo JA, Lacerda
JF, Prata MM: An assessment of the RIFLE
criteria for acute renal failure in hospital-

38 Uchino S, Bellomo R, Goldsmith D, Bates S,
Ronco C: An assessment of the RIFLE
criteria for acute renal failure in hospital-

39 Van Biesen W, Vanholder R, Lameire N: De-
fining acute renal failure: RIFLE and beyond.

40 Bagshaw SM, George C, Dinu I, Bellomo R:
A multi-centre evaluation of the RIFLE cri-
tera for early acute kidney injury in critically
ill patients. Nephrol Dial Transplant 2008;

41 Bagshaw SM, George C, Bellomo R: Early
acute kidney injury and sepsis: a multicentre

42 Kellum JA, Levin N, Bouman C, Lameire N:
Developing a consensus classification sys-
tem for acute renal failure. Curr Opin Crit
Care 2002;8:509–514.

43 Hoste EA, Kellum JA: Acute kidney injury:
epidemiology and diagnostic criteria. Curr
Opin Crit Care 2006;12:531–537.

44 Bagshaw SM, Gibney RT: Ideal determinants
for the initiation of renal replacement ther-
apy: timing, metabolic threshold or fluid bal-

45 Bagshaw SM, Uchino S, Bellomo R, Morin-
matsu H, Morgera S, Schetz M, Tan I, Bou-
man C, Macedo E, Gibney N, et al: Timing of renal replacement therapy and clinical out-

46 Bouman CS, Oudemans-Van Straaten HM,
Tijssen JG, Zandstra DF, Kecskesiovag J: Ef-
effects of early high-volume continuous veno-
venous hemofiltration on survival and re-
covery of renal function in intensive care
patients with acute renal failure: a prospec-
tive, randomized trial. Crit Care Med 2002;
30:2205–2211.

47 Gibney N, Hoste E, Burdman EA, Bunch-
ton M, Kher V, Viswanathan R, Mehta RL,
Ronco C: Timing of initiation and discon-
tinuation of renal replacement therapy in
AKI: unanswered key questions. Clin J Am

48 Guerin C, Girard R, Selli JM, Perdrix JP,
Ayzac L: Initial versus delayed acute renal
failure in the intensive care unit. A multi-
center prospective epidemiological study.
Rhone-Alpes Area Study Group on Acute
Renal Failure. Am J Respir Crit Care Med

49 Mehta RL, Pascual MT, Soroko S, Savage BR,
Himmelfarb J, Ikizler TA, Paganini EP,
Carrillo GM: Spectrum of acute renal fail-
ure in the intensive care unit: the PICARD

50 Paleysky PM: Clinical review: timing and
dose of continuous renal replacement ther-
apy in acute kidney injury. Crit Care 2007;11:
232.

51 Uchino S, Kellum JA, Bellomo R, Doig GS,
Morimatsu H, Morgera S, Schetz M, Tan I,
Bouman C, Macedo E, et al: Acute renal fail-
ure in critically ill patients: a multinational,
multicenter study. JAMA 2005;294:813–
818.

52 Andrade L, Ceto S, Seguro AC: Door-to-di-
yalysis time in daily hemodialysis in pa-
tients with leptospirosis: impact on mortal-

53 Brivet FG, Kleininknejf DJ, Loirat P, Landais
PJ: Acute renal failure in intensive care units –
causes, outcome, and prognostic factors of
hospital mortality; a prospective, multi-
center study. French Study Group on Acute
Renal Failure Critical Care Med 1996;24:192–
198.

54 Cosentino F, Chaff C, Piedmonte M: Risk
factors influencing survival in ICU acute re-
9(suppl 4):179–182.

55 Demirkilic U, Kuralay E, Yenicesu M, Caglar
K, Oz BS, Cingoz F, Gunay C, Yildirim V,
Ceylan S, Arslan M, et al: Timing of replace-
ment therapy for acute renal failure after car-

56 Elahi MM, Lim MY, Joseph RN, Dhanna-
man C, Ozbay BS, Cingoz F, Gunay C, Yildirim V,
Ceylan S, Arslan M, et al: Timing of replace-
ment therapy for acute renal failure after car-

57 Gettingis LG, Reynolds HN, Scalea T: Out-
come in post-traumatic acute renal failure
when continuous renal replacement therapy
is applied early vs. late. Intensive Care Med


